Skip to main content
Fig. 2 | Alzheimer's Research & Therapy

Fig. 2

From: Safety, tolerability, pharmacokinetics and pharmacodynamics of a single intravenous dose of SHR-1707 in healthy adult subjects: two randomized, double-blind, single-ascending-dose, phase 1 studies

Fig. 2

Mean serum concentration-time curve (semi-log scale) of SHR-1707 after a single intravenous administration. (A) Study CHN Part (1) (B) Study CHN Part (2) (C) Study AUS. Error bars indicate standard deviation. Follow-up was conducted up to day 78 for the 2, 6 and 20 mg/kg cohorts in Study CHN Part 1 and the 2 mg/kg cohort in Study AUS. For all other cohorts in the two studies, follow-up was done up to day 43. EOI, end of infusion

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193